“I want to roll out my strategy to them so that they know why we’re doing things, why the urgency, what are we trying to accomplish and really what it means to them,” Girshick told me during a recent visit to the Leadership Institute’s offices. It’s just one way an ultimate insider is in some ways acting as if she’s an outsider in her quest to transform Charles River which provides drug-development services. Girshick, who started at Charles River as an executive assistant in her home country of Germany, is just the third CEO in the company’s nearly 80-year history and the first unrelated to the founder.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as

Organic revenue returned to growth as biopharmaceutical demand strengthened.

CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.

Charles River Laboratories International (NYSE:CRL) reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earning

In August 2026, Charles River Laboratories International reported second-quarter revenue of US$1,004.08 million, swinging to a small net loss, and simultaneously cut its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share, largely due to losses tied to recent divestitures. Despite these GAAP headwinds, the company exceeded non-GAAP earnings expectations, raised its full-year adjusted EPS outlook, and highlighted strong momentum in its Discovery and Safety Assessment segment, pointing to...

Moby summary of Charles River Laboratories International, Inc.'s Q2 2026 earnings call

Charles River Laboratories International Inc (CRL) beats Q2 targets with a 1.19x book-to-bill, portfolio refinements boosting margins, and a new Cambodian NHP supply deal set to drive Q4 gains.

Shares of Charles River Laboratories blew out of a buy zone Wednesday after the medtech company hit its highest book-to-bill ratio in four years.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.

Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.

Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Charles River (CRL) delivered earnings and revenue surprises of +11.03% and +3.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Can Zimmer Biomet, Charles River Laboratories and Bio-Techne meet earnings expectations? See the MedTech trends and company-specific drivers in focus.

CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align Technology will add three new independent directors to its board and launch a review of its operations ‌following talks with activist investor Elliott Investment Management, the company said ‌on Wednesday. The three new board ​members, who have not yet been named, will be chosen for their expertise in healthcare technology, medical devices, global operations, and scaling high-growth businesses. Elliott, one of Wall Street's most prominent activist investors, has increasingly turned its attention to ‌healthcare companies over the past ⁠year, often pushing for board representation and strategic reviews to boost performance.

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 10.2% over the past six months while the S&P 500 was up 7.7%.

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...

ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.